- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07946341
A Study in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380
A Randomized, Double-blind, Placebo-controlled, Sequential, Multiple Ascending Dose (MAD) Study Following Oral Administration in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380
A study in Healthy Participants with Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, PK and PD of CS060380 following oral multiple ascending dose administration in healthy participants with elevated LDL-C.
Approximately 30 participants (10 participants per cohort: n=8 participants will receive active CS060380 and n=2 participants will be administered placebo) will be enrolled sequentially in 3 ascending dose groups. The proposed dose levels will range from 1.0 mg to 4.0 mg.
The next higher dose cohort will be enrolled only after the prior dose cohort has been discharged from the CPC on Day 17 and the SRC has reviewed all available safety/tolerability, PK/PD, and thyroid function data.
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Mary Purucker, MD
- Telefoonnummer: 1733 +1-240-673-0500
- E-mail: mary.purucker@pharmaron-us.com
Studie Locaties
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21201
- Pharmaron Clinical Pharmacology Center (CPC), Inc.
-
Contact:
- Mary Purucker, MD
- E-mail: mary.purucker@pharmaron-us.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
The participant provided signed and dated informed consent.
-
Male or female aged 18-65 years (inclusive).
-
Fasting LDL-C >110 mg/dL (2.85 mmol/L) at screening.
-
Female participants must meet one of the following:
- Postmenopausal status confirmed by follicle-stimulating hormone (FSH) testing, or
- Surgically sterile (medically documented), or
- If with childbearing potential, the participant must agree to use at least one highly effective contraceptive method in combination with an additional effective contraceptive method from study initiation until 3 months after the last dose, or
- Complete abstinence (if agreed by the participant).
Male participants, even if surgically sterilized (e.g., vasectomy), must:
- Use effective barrier contraception and refrain from sperm donation throughout the study and for 3 months after the last dose, or
- Complete abstinence (if agreed upon by the participant). Refer to Section 9.4 for detailed contraceptive requirements.
-
Normal renal function (estimated glomerular filtration rate [eGFR] ≥ 80 mL/min/1.73 m², calculated using the CKD-EPI equation).
-
Good general health, as judged by the Investigator based on: medical/surgical history, complete physical examination, vital signs, laboratory tests, and 12-lead ECG results (all findings either normal or with no clinically significant abnormalities).
-
No significant medical history; assessed to be in good general health at screening, with evaluations completed ≤ 28 days before the first dose.
-
Willingness and ability to: Understand and comply with study procedures/restrictions, complete the trial as planned and communicate effectively with the Investigator.
Exclusion Criteria:
-
Individuals with special dietary requirements unable to comply with standardized diets.
-
Females who are pregnant or lactating, those with pregnancy plans within 3 months post-trial, or female participants with positive pregnancy tests during screening/baseline periods.
-
Participants with febrile illness or active infection within 7 days prior to the first dose of the investigational drug.
-
Participants with positive urine drug screening results.
-
Participants with a history of drug/substance abuse within 5 years prior to the trial or positive drug screening at Day -1.
-
Participants receiving lipid-lowering therapy or with LDL-C > 190 mg/dL, or those with a history of coronary artery disease, cardiac arrhythmias, unexplained syncope, or family history of sudden cardiac arrest.
-
Participants with a history of QTc prolongation:
- QTcF ≥ 450 ms during screening;
- Hypocalcemia or family history of long QT syndrome;
- Use of QT/QTc-prolonging medications;
- ECG abnormalities deemed clinically significant by the Investigator.
-
Tobacco or nicotine product use within 3 months prior to screening or during the study until discharge.
-
Use of other investigational drugs within 40 days prior to enrollment or within ≥ 5 half-lives (whichever is longer).
-
Positive infectious disease screening results during screening (HIV antibody, HBsAg, HCV antibody).
-
Clinically significant laboratory abnormalities per Investigator judgment during screening.
-
Presence of clinically significant hypertension, defined as systolic blood pressure (SBP) > 145 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg, at Screening or Admission.
-
Blood loss > 50 mL within 40 days or > 500 mL within 56 days prior to dosing.
-
Regular alcohol consumption (> 1 unit/day) within 1 month prior to screening or positive alcohol test at screening or admission. [1 unit = 150 mL wine, 360 mL beer, or 45 mL 40% alcohol]. Alcohol consumption within 48 hours predose or during CRU stays.
-
Prescription/OTC medication use within 14 days prior to admission (Day -1) or ≥ 5 half-lives (whichever is longer); or use of any of the inhibitors or induces as listed in Appendix 1, CYP3A-, p-glycoprotein- (p-gp) or breast cancer resistance protein (BCRP)-modulating substances (e.g., herbs, grapefruit) within 14 days predose or ≥ 5 half-lives.
-
Thyroid disease history or clinically significant thyroid test abnormalities.
-
Hypersensitivity to thyroid medications.
-
Conditions potentially affecting drug ADME (e.g., gastrectomy, cholecystectomy, inflammatory bowel disease).
-
Clinically significant comorbidities (e.g., GI, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular diseases) that may compromise study conduct/interpretation or pose risks per Investigator assessment.
-
Hypersensitivity to investigational drug components, specific allergy history (asthma, urticaria, eczema), or atopic predisposition (allergy to ≥ 2 drugs/foods like milk/pollen).
-
Any condition deemed by the Investigator to jeopardize participant safety or study integrity.
-
Abnormal thyroid function tests (total/free T3, total/free T4, TSH) beyond reference ranges during screening.
-
Troponin > ULN during screening or Day -1 periods.
-
Presence of any psychiatric disorder or impaired mental capacity that may compromise the ability to provide informed consent, affect the assessment of efficacy, or impair compliance with the study protocol.
-
Any other condition that, in the opinion of the investigator, may jeopardize the safety of the subject or compromise the quality of the clinical study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: MAD Cohort 1: CS060380 1.0 mg
CS060380 1.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions. |
CS060380 is administered orally once daily (QD) Matching placebo is administered orally once daily (QD)
Andere namen:
|
|
Experimenteel: MAD Cohort 2: CS060380 2.0 mg
CS060380 2.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions. |
CS060380 is administered orally once daily (QD) Matching placebo is administered orally once daily (QD)
Andere namen:
|
|
Experimenteel: MAD Cohort 3: CS060380 4.0 mg
CS060380 4.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions. |
CS060380 is administered orally once daily (QD) Matching placebo is administered orally once daily (QD)
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adverse Events during the study period
Tijdsspanne: Baseline to Day28
|
To characterize the safety and tolerability of multiple doses of CS060380 in healthy participants |
Baseline to Day28
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cmax
Tijdsspanne: Day1
|
Pharmacokinetics: Maximum concentration during a dosing interval |
Day1
|
|
Tmax
Tijdsspanne: Day1 Day17
|
Pharmacokinetics: Time to maximum plasma concentration |
Day1 Day17
|
|
t1/2
Tijdsspanne: Day1
|
Pharmacokinetics: Terminal elimination half-life |
Day1
|
|
AUClast
Tijdsspanne: Day1
|
Pharmacokinetics: AUC from time 0 to the last measurable concentration |
Day1
|
|
AUCinf
Tijdsspanne: Day1
|
Pharmacokinetics: area under the plasma concentration-time curve from time zero to infinity |
Day1
|
|
CL/F
Tijdsspanne: Day1
|
Pharmacokinetics: apparent total plasma clearance |
Day1
|
|
Cmax,ss
Tijdsspanne: Day14
|
Pharmacokinetics: steady-state maximum plasma concentration |
Day14
|
|
Cmin
Tijdsspanne: Day14
|
Pharmacokinetics: minimum concentration during a dosing interval |
Day14
|
|
t1/2,ss
Tijdsspanne: Day14
|
Pharmacokinetics: steady-state terminal elimination half-life |
Day14
|
|
AUCτ (τ = 24 hours)
Tijdsspanne: Day14
|
Pharmacokinetics: AUC from time 0 to 24 hours after dosing |
Day14
|
|
CL/Fss
Tijdsspanne: Day14
|
Pharmacokinetics: steady-State apparent total plasma clearance |
Day14
|
|
DF
Tijdsspanne: Day14
|
Pharmacokinetics: degree of fluctuation |
Day14
|
|
Cavg
Tijdsspanne: Day14
|
Pharmacokinetics: mean plasma concentration during a dosing interval |
Day14
|
|
Rac_AUCτ
Tijdsspanne: Day14
|
Pharmacokinetics: accumulation ratio based on area under the plasma concentration-time curve |
Day14
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
LDL-C
Tijdsspanne: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
Pharmacodynamics: low-density lipoprotein cholesterol |
Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
|
HDL-C
Tijdsspanne: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
Pharmacodynamics: high-density lipoprotein cholesterol |
Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
|
TG
Tijdsspanne: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
Pharmacodynamics: triglycerides |
Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
|
TC
Tijdsspanne: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
Pharmacodynamics: total cholesterol |
Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
|
SHBG
Tijdsspanne: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
Pharmacodynamics: sex hormone binding globulin |
Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
|
Total/free T3
Tijdsspanne: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
To explore the effects on thyroid function parameters of CS060380 |
Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
|
total/free T4,
Tijdsspanne: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
To explore the effects on thyroid function parameters of CS060380 |
Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
|
TSH
Tijdsspanne: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
To explore the effects on thyroid function parameters of CS060380 |
Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Mary Purucker, MD, Pharmaron Clinical Pharmacology Center (CPC), Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- CS060380-MASH-US-I-05
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .